U.S. cigarette maker 22nd Century Group, Inc. said it entered an agreement to use human cell-based testing from CannaMetrix, LLC, Henrietta, New York, as it looks to expand its line of cannabis products and intellectual property. 22nd Century said it has realigned its cannabis strategy to target upstream segments of the cannabinoid value chain after having secured four out of five key partnerships needed to maximize its position in the sector; the company now has partners in plant profiling, biotechnology, cultivation and extraction, and is looking to establish relationships with plant breeders.
Posted By: HempToday® March 4, 2021
Like HempToday? How you can support us
Your donations help us to keep HempToday open for all readers, regardless of what they can afford to pay. Through this “information equality” we're able to support hemp entrepreneurs and stakeholders all over the world by keeping a spotlight on hemp and all the promise it offers for economic development and healing our planet.